IRIS
DIGIACOMO, GRAZIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.925
AS - Asia 1.454
EU - Europa 1.276
SA - Sud America 269
AF - Africa 80
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.010
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.896
IT - Italia 576
SG - Singapore 499
CN - Cina 367
VN - Vietnam 265
BR - Brasile 202
IE - Irlanda 156
SE - Svezia 113
HK - Hong Kong 106
DE - Germania 105
FR - Francia 59
NL - Olanda 54
ZA - Sudafrica 52
IN - India 50
RU - Federazione Russa 37
AR - Argentina 29
BE - Belgio 29
GB - Regno Unito 29
FI - Finlandia 22
AT - Austria 20
BD - Bangladesh 16
PK - Pakistan 16
IQ - Iraq 15
KR - Corea 15
JP - Giappone 14
UA - Ucraina 14
ID - Indonesia 13
MX - Messico 13
TR - Turchia 13
ES - Italia 12
PL - Polonia 12
CI - Costa d'Avorio 11
CA - Canada 10
CO - Colombia 9
EC - Ecuador 9
PH - Filippine 9
LT - Lituania 8
CZ - Repubblica Ceca 7
SA - Arabia Saudita 7
UZ - Uzbekistan 6
VE - Venezuela 6
PY - Paraguay 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
JO - Giordania 4
OM - Oman 4
TN - Tunisia 4
BO - Bolivia 3
CH - Svizzera 3
CL - Cile 3
IR - Iran 3
JM - Giamaica 3
LU - Lussemburgo 3
MY - Malesia 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
AZ - Azerbaigian 2
EG - Egitto 2
GA - Gabon 2
HU - Ungheria 2
KE - Kenya 2
KG - Kirghizistan 2
LB - Libano 2
LK - Sri Lanka 2
MA - Marocco 2
MD - Moldavia 2
MK - Macedonia 2
PE - Perù 2
PS - Palestinian Territory 2
QA - Qatar 2
TW - Taiwan 2
AD - Andorra 1
AL - Albania 1
AO - Angola 1
BW - Botswana 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KW - Kuwait 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TZ - Tanzania 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.010
Salva come PNG Salva come JPEG
Città #
Singapore 276
Dallas 262
Ann Arbor 234
Ashburn 227
Dublin 156
Chandler 148
Parma 146
San Jose 131
Hong Kong 102
Santa Clara 101
Ho Chi Minh City 76
Hanoi 59
Los Angeles 59
Beijing 56
Johannesburg 50
Boardman 49
Milan 49
Shanghai 47
Munich 46
Dearborn 42
Hefei 40
New York 34
Chicago 30
Council Bluffs 28
Modena 28
Lauterbourg 26
Bologna 25
Nanjing 21
Princeton 21
Redmond 17
Reggio Emilia 17
São Paulo 17
Bremen 16
Buffalo 15
Vienna 15
Moscow 14
Columbus 13
Da Nang 13
Frankfurt am Main 13
Helsinki 13
Brussels 12
Jakarta 12
Wayne 12
Abidjan 11
Denver 11
Rome 11
Seoul 11
Amsterdam 10
Florence 10
Stockholm 10
The Dalles 10
Tokyo 10
Warsaw 10
Wilmington 10
Bari 9
Izmir 9
Nuremberg 9
San Mateo 9
Shenyang 9
Turku 9
Chennai 8
Des Moines 8
Haiphong 8
Jinan 8
London 8
Verona 8
Woodbridge 8
Binche 7
Nanchang 7
Seattle 7
Atlanta 6
Baghdad 6
Belo Horizonte 6
Brasília 6
Dhaka 6
Dong Ket 6
Follonica 6
Fremont 6
Houston 6
Leuven 6
Marseille 6
Phủ Lý 6
Tianjin 6
Wuhan 6
Bengaluru 5
Biên Hòa 5
Campinas 5
Hebei 5
Lahore 5
Phoenix 5
Tashkent 5
Turin 5
Amman 4
Bitonto 4
Bogotá 4
Brescia 4
Casalgrande 4
Düsseldorf 4
Guangzhou 4
Kunming 4
Totale 3.169
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 243
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 188
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 145
Biological hallmarks and new therapeutic approaches for the treatment of pdac 145
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 135
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 132
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 131
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 130
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 127
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 124
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 120
State of the art and perspectives in pediatric hepatocellular carcinoma 116
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 114
Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells 111
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 110
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 106
Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway 101
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition 71
Prostaglandin E2 transactivates the colony-stimulating factor-1 receptor and synergizes with Colony-stimulating factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2 65
Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies 44
Totale 5.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202175 0 0 0 0 0 0 0 0 0 14 28 33
2021/2022176 22 13 24 8 3 3 28 4 11 8 8 44
2022/2023619 44 56 45 39 48 58 12 60 198 6 36 17
2023/2024390 14 23 21 14 48 56 33 25 12 32 55 57
2024/20251.050 38 40 60 70 101 110 114 69 107 92 102 147
2025/20262.185 182 213 349 218 296 116 238 77 337 159 0 0
Totale 5.088